Xencor, Inc. (XNCR) Releases Earnings Results
Xencor, Inc. (NASDAQ:XNCR) released its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.10, Morningstar.com reports. Xencor had a negative net margin of 121.04% and a negative return on equity of 14.14%. The firm had revenue of $13.34 million for the quarter, compared to analysts’ expectations of $8.15 million.
Xencor (NASDAQ:XNCR) opened at 23.29 on Wednesday. Xencor has a 52-week low of $18.45 and a 52-week high of $29.38. The firm has a 50 day moving average of $22.46 and a 200-day moving average of $23.07. The stock has a market cap of $1.09 billion, a PE ratio of 65.98 and a beta of 2.14.
ILLEGAL ACTIVITY WARNING: “Xencor, Inc. (XNCR) Releases Earnings Results” was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/08/09/xencor-inc-xncr-releases-earnings-results.html.
In related news, Director Bruce L. A. Carter sold 12,400 shares of the firm’s stock in a transaction dated Friday, May 26th. The shares were sold at an average price of $22.19, for a total value of $275,156.00. Following the transaction, the director now owns 83,344 shares of the company’s stock, valued at approximately $1,849,403.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder John S. Stafford III purchased 1,500 shares of Xencor stock in a transaction that occurred on Friday, June 16th. The stock was bought at an average cost of $19.67 per share, for a total transaction of $29,505.00. The disclosure for this purchase can be found here. In the last three months, insiders sold 34,766 shares of company stock worth $739,408. Insiders own 4.14% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP increased its position in Xencor by 254.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 182,256 shares of the biopharmaceutical company’s stock valued at $4,797,000 after buying an additional 130,778 shares in the last quarter. Norges Bank bought a new position in Xencor during the fourth quarter valued at approximately $15,601,000. Teachers Advisors LLC increased its position in Xencor by 2.0% in the fourth quarter. Teachers Advisors LLC now owns 319,914 shares of the biopharmaceutical company’s stock valued at $8,420,000 after buying an additional 6,392 shares in the last quarter. Creative Planning increased its position in Xencor by 2.7% in the first quarter. Creative Planning now owns 38,400 shares of the biopharmaceutical company’s stock valued at $919,000 after buying an additional 1,000 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. increased its position in Xencor by 80.0% in the first quarter. Candriam Luxembourg S.C.A. now owns 135,000 shares of the biopharmaceutical company’s stock valued at $3,229,000 after buying an additional 60,000 shares in the last quarter. 74.12% of the stock is currently owned by institutional investors.
XNCR has been the topic of a number of analyst reports. Zacks Investment Research cut shares of Xencor from a “buy” rating to a “hold” rating in a research report on Saturday, April 29th. Wedbush restated an “outperform” rating and issued a $29.00 price objective on shares of Xencor in a research report on Wednesday, May 10th. Finally, Canaccord Genuity restated a “buy” rating and issued a $36.00 price objective on shares of Xencor in a research report on Tuesday. Four analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $29.33.
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.